By Stephen Nakrosis
Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16.
The company said Chang, who will also serve as chief scientific officer, will establish and lead research priorities within its rare disease, oncology, inflammation and cardiometabolic therapeutic areas.
Chang succeeds Ray Deshaies, whose departure was announced earlier this year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 20, 2024 16:23 ET (21:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.